Physician profile
Mark D Goodman
NPI 1326157124
$2,747.32
in general payments reported to CMS, 2019-2025
20 companies · $14.99 in 2025
The $14.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $402 · 2021: $425 · 2022: $485 · 2023: $609 · 2024: $86.74 · 2025: $14.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,021.22 | 2019-2024 | Biktarvy, Epclusa |
| Viiv Healthcare Company | $822.27 | 2019-2024 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $172.88 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $141.50 | 2021-2025 | Pifeltro, Dificid, Delstrigo |
| Bayer Healthcare Pharmaceuticals INC. | $126.29 | 2021-2023 | |
| Amgen INC. | $76.19 | 2019 | |
| Janssen Products, Lp | $72.00 | 2019 | |
| Biogen, INC. | $71.81 | 2019-2023 | Vumerity |
| Novo Nordisk INC | $70.35 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $27.19 | 2022-2023 | Farxiga |
| Abbott Laboratories | $21.81 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $17.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.28 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.35 | 2022 | |
| Antares Pharma, INC. | $13.98 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.76 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.15 | 2020 | |
| Strongbridge US INC. | $12.85 | 2020 | |
| Neuronetics, INC. | $11.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.